Frbrir kennarar og maur mtar hugmyndina sna og sr hvort a er mgulegt a koma henni framkvmd
After 68 weeks, participants receiving a 2.4 mg weekly semaglutide dose experienced a 49% reduction in C-reactive protein (CRP), while those on a 1 mg weekly dose saw a 42% reduction compared to placebo
New indications, such as cardiovascular risk reduction and obstructive sleep apnea, are redefining the value proposition of these drugs and influencing both prescribing patterns and reimbursement decisions
In recent years, data have been accumulated suggesting effects of GLP-1 RAs on surrogate HF outcomes in HF patients across LVEF, including cardiac structure and function, exercise capacity and quality of life
Skin changes during menopause, including loss of collagen, elasticity, and hydration, can be exacerbated by rapid weight loss